# OnCo record paper-paola-1-nejm-2019 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-paola-1-nejm-2019/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-paola-1-nejm-2019" ;
  schema:name "PAOLA-1: olaparib added to bevacizumab maintenance in newly diagnosed ovarian cancer, with benefit confined to HRD-positive tumours"@en ;
  schema:description "Adding the PARP inhibitor olaparib to bevacizumab after first-line chemotherapy for advanced ovarian cancer roughly doubled the time without progression in women whose tumours had defective DNA repair, but did nothing for those without it."@en ;
  schema:url <https://onco.cc/key-papers/paper-paola-1-nejm-2019/> ;
  schema:dateModified "2026-09-08"^^xsd:date ;
  schema:citation <https://doi.org/10.1056/NEJMoa1911361>, <https://clinicaltrials.gov/study/NCT02477644> ;
  schema:sameAs <https://doi.org/10.1056/NEJMoa1911361> ;
  schema:datePublished "2019"^^xsd:gYear ;
  schema:author "Ray-Coquard I, Pautier P, Pignata S, et al." ;
  onco:cancers <https://onco.cc/cancers/ovarian/> ;
  onco:technologies <https://onco.cc/technologies/parp-inhibitor/>, <https://onco.cc/technologies/hrd-testing/>, <https://onco.cc/technologies/antiangiogenic/>, <https://onco.cc/technologies/synthetic-lethality-approaches/> ;
  onco:targets <https://onco.cc/targets/parp/>, <https://onco.cc/targets/brca/>, <https://onco.cc/targets/vegf/> ;
  onco:drugs <https://onco.cc/drugs/olaparib/> ;
  onco:companies <https://onco.cc/companies/astrazeneca/>, <https://onco.cc/companies/merck/> ;
  onco:institutions <https://onco.cc/institutions/gemelli/> ;
  onco:terms <https://onco.cc/terms/hrd/>, <https://onco.cc/terms/synthetic-lethality/>, <https://onco.cc/terms/pfs/>, <https://onco.cc/terms/os/>, <https://onco.cc/terms/germline-vs-somatic/> ;
  onco:people <https://onco.cc/people/giovanni-scambia/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-biomarker-validation/>, <https://onco.cc/bottlenecks/b-dormancy-mrd/>, <https://onco.cc/bottlenecks/b-drug-pricing/> ;
  onco:journals <https://onco.cc/journals/nejm/> .